94 related articles for article (PubMed ID: 2519427)
21. Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites.
Tuttolomondo A; Pinto A; Parrinello G; Licata G
Semin Nephrol; 2011 Nov; 31(6):513-22. PubMed ID: 22099508
[TBL] [Abstract][Full Text] [Related]
22. Combined ascitic--fluid and furosemide infusion: a therapeutic option for massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis.
Onuigbo MA; Ozoh JO; Nusiem CA; Onyeagocha AC; Nwaneri O; Offodile AA; Ijoma CK
Cent Afr J Med; 1991 Aug; 37(8):244-7. PubMed ID: 1807797
[TBL] [Abstract][Full Text] [Related]
23. Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal.
Sansoè G; Silvano S; Mengozzi G; Smedile A; Todros L; Baronio M; Bonardi L; Rizzetto M
Am J Gastroenterol; 2002 Sep; 97(9):2383-90. PubMed ID: 12358261
[TBL] [Abstract][Full Text] [Related]
24. Refractory ascites: definition, pathogenesis and treatment.
Laffi G; La Villa G; Pinzani M; Foschi M; Carloni V; Casini Raggi V; Gentilini P
Ann Ital Med Int; 1993; 8(1):38-46. PubMed ID: 8485009
[TBL] [Abstract][Full Text] [Related]
25. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites.
Gerbes AL; Gülberg V; Waggershauser T; Holl J; Reiser M
Hepatology; 1998 Sep; 28(3):683-8. PubMed ID: 9731559
[TBL] [Abstract][Full Text] [Related]
26. Effects of angiotensin-converting enzyme inhibition on renal adaptations to acute furosemide administration in conscious rats.
Bak M; Shalmi M; Petersen JS; Poulsen LB; Christensen S
J Pharmacol Exp Ther; 1993 Jul; 266(1):33-40. PubMed ID: 8392557
[TBL] [Abstract][Full Text] [Related]
27. Effects of single dose of 50mg captopril in patients with liver cirrhosis and ascites.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Hepatogastroenterology; 2000; 47(33):767-70. PubMed ID: 10919029
[TBL] [Abstract][Full Text] [Related]
28. Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis.
Woitas RP; Heller J; Stoffel-Wagner B; Spengler U; Sauerbruch T
Hepatology; 1997 Oct; 26(4):858-64. PubMed ID: 9328305
[TBL] [Abstract][Full Text] [Related]
29. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
30. Ascites kinetics in cirrhosis: effects of rapid volume expansion and diuretic administration.
Rector WG
J Lab Clin Med; 1988 Feb; 111(2):166-72. PubMed ID: 3339270
[TBL] [Abstract][Full Text] [Related]
31. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites.
Stergiou GS; Mayopoulou-Symvoulidou D; Mountokalakis TD
Miner Electrolyte Metab; 1993; 19(2):86-90. PubMed ID: 8377729
[TBL] [Abstract][Full Text] [Related]
32. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
Wong W; Liu P; Blendis L; Wong F
Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
[TBL] [Abstract][Full Text] [Related]
33. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis].
Tesar V; Kotal P; Petrtýl J; Bukovská J; Kozáková M; Brodanová M; Horký K; Kordac V
Cas Lek Cesk; 1990 May; 129(21):657-64. PubMed ID: 2369756
[TBL] [Abstract][Full Text] [Related]
35. Effect of dipyridamole on kidney function in cirrhosis.
Llach J; Ginès P; Arroyo V; Salmerón JM; Ginès A; Jiménez W; Gaya J; Rivera F; Rodés J
Hepatology; 1993 Jan; 17(1):59-64. PubMed ID: 8423042
[TBL] [Abstract][Full Text] [Related]
36. Urinary prostaglandin E2 excretion, sodium retention, and diuretic responsiveness in patients with chronic liver disease.
Rector WG
Am J Gastroenterol; 1987 Apr; 82(4):347-51. PubMed ID: 3471082
[TBL] [Abstract][Full Text] [Related]
37. [Significances of plasma levels of neuropeptide Y pre- and post-treatment in patients with decompensated cirrhosis and ascites].
Li GW; Wu LD; Zhu Y
Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):483-4. PubMed ID: 12754138
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis.
Luca A; García-Pagán JC; Bosch J; Feu F; Jiménez W; Ginés A; Fernández M; Escorsell A; Arroyo V; Rodés J
Hepatology; 1995 Sep; 22(3):753-8. PubMed ID: 7657279
[TBL] [Abstract][Full Text] [Related]
39. [Liver cirrhosis: pathogenesis of ascites and disturbance of renal function].
Toledo C; Ginés P; Arroyo V
Rev Med Chil; 1992 Feb; 120(2):180-7. PubMed ID: 1340557
[TBL] [Abstract][Full Text] [Related]
40. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.
Misra VL; Vuppalanchi R; Jones D; Hamman M; Kwo PY; Kahi C; Chalasani N
Aliment Pharmacol Ther; 2010 Oct; 32(8):1044-50. PubMed ID: 20937051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
